Physician profile
Philip Pearson
NPI 1609938489
$1,080.43
in general payments reported to CMS, 2019-2025
16 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $65.61 · 2023: $251 · 2024: $150 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $311.45 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Calyxo, INC. | $146.06 | 2025 | Cvac Aspiration System |
| Amgen INC. | $104.61 | 2019 | |
| Astellas Pharma US INC | $94.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $92.16 | 2019 | |
| Axonics, INC. | $64.50 | 2023 | Bulkamid, Axonics |
| Exelixis INC. | $47.45 | 2019-2020 | |
| Pfizer INC. | $41.05 | 2019 | |
| Baxter Healthcare | $37.50 | 2019 | |
| Janssen Biotech, INC. | $33.89 | 2019 | |
| Intuitive Surgical, INC. | $24.31 | 2023 | Da Vinci Surgical System |
| Neotract INC. | $20.62 | 2019 | |
| Puma Biotechnology, INC. | $18.22 | 2019 | |
| Foundation Medicine, INC. | $16.92 | 2019 | |
| Celgene Corporation | $15.67 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.